Splet22. feb. 2024 · Entered into definitive agreement to sell iNK cell franchise and out-license certain gene editing technologies to Shoreline Biosciences. CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the fourth ... Splet“Shoreline Biosciences is a rapidly growing company focused on creating immunotherapies for curing cancer. The energetic and collaborative environment …
Grant Jobs, Employment in Shelter Island, CA Indeed.com
SpletShoreline Biosciences, Inc. is a trailblazer in the cell therapy space, propelling forward with our state-of-the-art iPSC platform with exclusive licensing of cutting-edge technologies of... Splet19. jan. 2024 · Editas Medicine ( NASDAQ: EDIT) announced an agreement with privately-held Shoreline Biosciences on Thursday to sell its natural killer cell ( (iNK)) programs and related manufacturing ... springfield xd 9mm 16 round magazine
Shoreline Biosciences Scientist I, Analytical Development in San …
Splet1,008 Grant jobs available in Cardiff-by-the-Sea, CA on Indeed.com. Apply to Executive Assistant, Grant Writer, Estimator and more! SpletTo attend this teleconference, live by telephone: Dial-in: (877) 545-0523 (North America); (973) 528-0016 (International). Verbal Access Code: 519732 (or say Pressure BioSciences Conference Call) For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, April 19, 2024. Splet16. mar. 2024 · Shoreline Biosciences Presents Data at AACR 2024 Demonstrating Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells Mar 16, 2024 (PRNewswire via COMTEX) -- PR Newswire SAN DIEGO ... springfield xd 9mm clip